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Abstract 32 
A toxicovenomic study was performed on the venom of the green mamba, 33 
Dendroaspis angusticeps. Forty-two different proteins were identified in the venom of 34 
D. angusticeps, in addition to the nucleoside adenosine. The most abundant proteins 35 
belong to the three-finger toxin (3FTx) (69.2%) and the Kunitz-type proteinase inhibitor 36 
(16.3%) families. Several sub-subfamilies of the 3FTxs were identified, such as Orphan 37 
Group XI (Toxin F-VIII), acetylcholinesterase inhibitors (fasciculins), and aminergic 38 
toxins (muscarinic toxins, synergistic-like toxins, and adrenergic toxins). Remarkably, 39 
no D-neurotoxins were identified. Proteins of the Kunitz-type proteinase inhibitor 40 
family include dendrotoxins. Toxicological screening revealed a lack of lethal activity 41 
in all RP-HPLC fractions, except one, at the doses tested. Thus, the overall toxicity 42 
depends on the synergistic action of various types of proteins, such as dendrotoxins, 43 
fasciculins, and probably other synergistically-acting toxins. Polyspecific antivenoms 44 
manufactured in South Africa and India were effective in the neutralization of venom-45 
induced lethality. These antivenoms also showed a pattern of broad immunorecognition 46 
of the different HPLC fractions by ELISA and immunoprecipitated the crude venom by 47 
gel immunodiffusion. The synergistic mechanism of toxicity constitutes a challenge for 48 
the development of effective recombinant antibodies, as it requires the identification of 49 
the most relevant synergistic toxins. 50 
(197 words) 51 
Keywords: Dendroaspis angusticeps; Green mamba; Snake venom; Proteomics; 52 
Toxicovenomics: Antivenoms.  53 
54 
Biological significance 55 
Envenomings by elapid snakes of the genus Dendroaspis, collectively known as 56 
mambas, represent a serious medical problem in sub-Saharan Africa. The development 57 
of novel antivenoms and of recombinant neutralizing antibodies demands the 58 
identification of the most relevant toxins in these venoms. In this study, a bottom-up 59 
approach was followed for the study of the proteome of the venom of the Eastern green 60 
mamba, D. angusticeps. Forty-two different proteins were identified, among which the 61 
three-finger toxin (3FTx) family, characteristic of elapid venoms, was the most 62 
abundant, followed by the Kunitz-type proteinase inhibitor family. In addition, several 63 
other protein families were present in the venom, together with the nucleoside 64 
adenosine. No D-neurotoxins were identified within the family of 3FTxs in the venom 65 
of D. angusticeps, in contrast to the venom of D. polylepis, in which D-neurotoxins are 66 
largely responsible for the toxicity. With one exception, HPLC fractions from D. 67 
angusticeps venom did not kill mice at the doses tested. This underscores that the 68 
toxicity of the whole venom is due to the synergistic action of various components, such 69 
as fasciculins and dendrotoxins, and probably other synergistically-acting toxins. Thus, 70 
the venoms of these closely related species (D. angusticeps and D. polylepis) seem to 71 
have different mechanisms to subdue their prey, which may be related to different prey 72 
preferences, as D. angusticeps is predominantly arboreal, whereas D. polylepis lives 73 
mostly in open bush country and feeds mainly on mammals. It is therefore likely that 74 
the predominant clinical manifestations of human envenomings by these species also 75 
differ, although in both cases neurotoxic manifestations predominate. Polyspecific 76 
antivenoms manufactured in South Africa and India were effective in the neutralization 77 
of venom-induced lethality in mice and showed a pattern of broad immunorecognition 78 
of the various venom fractions. It is necessary to identify the toxins responsible for the 79 
synergistic mode of toxicity in this venom, since they are the targets for the 80 
development of recombinant antibodies for the treatment of envenomings. 81 
82 
1. Introduction 83 
The Eastern green mamba (Dendroaspis angusticeps) is a highly venomous 84 
elapid found primarily in southeastern Africa (Figure 1). First described by Smith in 85 
1848 [1], D. angusticeps is a relatively small mamba species, averaging 1.4 m in length. 86 
Due to its arboreal, shy, and elusive nature, human envenomings are less frequent than 87 
those inflicted by the more territorial Dendroaspis polylepis (black mamba) [2,3]. Adult 88 
specimens of D. angusticeps have a brilliant emerald to lime green coloration, providing 89 
them with an excellent camouflage in their natural habitat of the tropical rainforests in 90 
the coastal lowlands of Southeast Africa [4]. D. angusticeps is, however, also found in 91 
areas with coastal bush, dune, and montane forest [5], as well as in closer proximity to 92 
humans, when residing in farm trees, such as citrus, mango, coconut, and cashew [6]. 93 
Due to its color and habitat, D. angusticeps is often mistaken for a harmless tree snake, 94 
why people often do not take proper precaution [2,3]. D. angusticeps preferably preys 95 
on warm-blooded animals, such as rodents, bats, birds, and nestlings, but also on eggs 96 
[4]. 97 
Despite a low number of human envenomings reported, but due to its potent 98 
neurotoxic venom, D. angusticeps is classified as a category 1 snake, which is the 99 
highest level of medically important snakes, according to the WHO [7]. Furthermore, its 100 
high abundance, particularly in Kenya, Tanzania, Mozambique, Malawi, eastern 101 
Zimbabwe, and the Republic of South Africa, makes this a snake of high 102 
epidemiological relevance [7]. Severe envenomings by D. angusticeps can lead to rapid 103 
mortality within only 30 minutes of a bite [6]. The typical clinical manifestations 104 
include swelling of the bitten area, dizziness, nausea, difficult breathing, irregular 105 
heartbeat, and respiratory paralysis [6]. These life-threatening symptoms may escalate 106 
rapidly, but deaths are rare when effective antivenom is administered timely [6]. 107 
Given the medical importance of D. angusticeps, it is necessary to have a 108 
thorough understanding of the composition of its venom, as well as of the underlying 109 
mechanisms for venom pathophysiology in human victims. Furthermore, preclinical 110 
assessment of antivenoms is critical for predicting efficacy of snakebite envenoming 111 
therapy, which may be used to guide clinicians in the treatment of snakebites by D. 112 
angusticeps. Currently, only the SAIMR Polyvalent Snake Antivenom from the South 113 
African Vaccine Producers is claimed to be effective against D. angusticeps, although it 114 
is possible that other polyvalent antivenoms raised against the venoms of other mamba 115 
species may be effective in neutralization of D. angusticeps venom. 116 
The venom of D. angusticeps has not undergone a full proteomics evaluation, 117 
and its quantitative protein composition is not known. Nevertheless, several biochemical 118 
and pharmacological studies have been performed on different toxins from D. 119 
angusticeps venom [8–11]. These studies report that this venom contains several 120 
neurotoxins, such as the fasciculins [10] and dendrotoxins [8,9], which are unique to the 121 
Dendroaspis genus [12,13]. This venom also contains a number of other toxins of the 122 
three-finger toxin family (3FTx), such as muscarinic toxins, adrenergic toxins, and 123 
synergistic-type toxins [14–16]. 124 
 The dendrotoxins, of structural similarity to the Kunitz-type serine protease 125 
inhibitors, target the presynaptic voltage-gated potassium channels with high specificity, 126 
facilitating the release of acetylcholine from the presynaptic nerve terminals, causing 127 
excitatory activity [17,18]. Other important neurotoxins of the 3FTx family present in 128 
D. angusticeps venom are the fasciculins, which prolong the presence of acetylcholine 129 
in the neuromuscular junction by inhibiting acetylcholinesterase, leading to muscle 130 
fasciculations [10]. Although the venom composition of D. angusticeps has not been 131 
elucidated, a study of the venom of the closely related and more feared relative, D. 132 
polylepis (black mamba), has recently been reported [19]. According to this study, D. 133 
polylepis venom is dominated by α-neurotoxins from the 3FTx family and dendrotoxins 134 
(BPTI-type/Kunitz type protease inhibitors). It is therefore of relevance to study the 135 
venom proteome of D. angusticeps in order to identify similarities and differences with 136 
that of D. polylepis.  137 
Toxicovenomics defines the recent convergence between toxicological 138 
evaluation of toxins and venomics [20,21]. Together with antivenomics, this tool may 139 
help provide a better understanding of D. angusticeps venom, the relative importance of 140 
different proteins for toxicity, and how venom toxicity may best be abrogated. While 141 
previous investigations of D. angusticeps have focused on the biochemical and 142 
pharmacological features of the toxins, recent advances in the field of venomics and 143 
antivenomics facilitate development of novel antivenoms through rational and 144 
knowledge-based interpretation of pharmacological relevant toxins [22]. 145 
Here, we report the first full toxicovenomics analysis of D. angusticeps, a 146 
quantitative estimation of its venome, and a preclinical and immunochemical 147 
assessment of three antivenoms against D. angusticeps venom. 148 
 149 
2. Materials and Methods 150 
2.1 Snake venom 151 
 Venom from D. angusticeps was obtained from Latoxan SAS, Valence, France, 152 
from a pool of 50 specimens collected in Tanzania. 153 
 154 
2.2 Venom separation by reverse-phase HPLC and SDS-PAGE  155 
The ‘snake venomics’ analytical strategy [23] involving fractionation of crude 156 
venom by a combination of RP-HPLC and SDS-PAGE separation steps, was followed. 157 
Venom (2 mg) was dissolved in 200 μL of water containing 0.1% trifluoroacetic acid 158 
(TFA; solution A) and separated by RP-HPLC (Agilent 1200) on a C18 column (250 x 159 
4.6 mm, 5 μm particle; Teknokroma). Elution was carried out at 1 mL/min by applying 160 
a gradient towards solution B (acetonitrile, containing 0.1% TFA): 0% B for 5 min, 0–161 
15% B over 10 min, 15–45% B over 60 min, 45–70% B over 10 min, and 70% B over 9 162 
min, as previously described [24]. Fractions, collected manually, were dried in a 163 
vacuum centrifuge, redissolved in water, reduced with 5% E-mercaptoethanol at 100 °C 164 
for 5 min, and further separated by SDS-PAGE in 15% gels. Proteins were stained with 165 
colloidal Coomassie blue G-250, and gel images were acquired on a ChemiDoc® 166 
recorder using ImageLab® software (Bio-Rad). 167 
 168 
2.3 Protein identification by tandem mass spectrometry of tryptic peptides 169 
Protein bands were excised from the polyacrylamide gels and subjected to 170 
reduction (10 mM dithiothreitol), alkylation (50 mM iodoacetamide), and overnight in-171 
gel digestion with sequencing grade trypsin (Sigma), in 50 mM ammonium bicarbonate 172 
at 37 °C. Tryptic peptides were extracted with 50% acetonitrile containing 1% TFA, and 173 
analyzed by MALDI-TOF-TOF on an AB4800-Plus Proteomics Analyzer (Applied 174 
Biosystems). Peptides were mixed with an equal volume of saturated α-cyano-175 
hydroxycinnamic acid (in 50% acetonitrile, 0.1% TFA), and spotted (1 μL) onto an 176 
Opti-TOF 384-well plate, dried, and analyzed in positive reflector mode. TOF spectra 177 
were acquired using 500 shots at a laser intensity of 3000. Selection of the ten most 178 
intense precursor ions was done automatically and their TOF/TOF fragmentation 179 
spectra were acquired using 500 shots at a laser intensity of 3900. External calibration 180 
in each run was performed with CalMix® standards (ABSciex) spotted onto the same 181 
plate. Resulting spectra were searched against the UniProt/SwissProt database for 182 
Serpentes (20150217) using ProteinPilot® v.4 and the Paragon® algorithm (ABSciex) at 183 
≥ 95% confidence, or, in few cases, manually interpreted and the deduced sequences 184 
searched using BLAST (http://blast.ncbi.nlm.nih.gov) for protein family assignment by 185 
similarity. 186 
 187 
2.4 Relative protein abundance estimations 188 
 Relative abundance of the venom proteins was estimated by integrating the areas 189 
of their chromatographic peaks at 215 nm, roughly corresponding to peptide bond 190 
abundance, using the ChemStation® software (Agilent) [23]. In the case where HPLC 191 
peaks contained several electrophoretic bands, their percentage distributions were 192 
assigned by densitometry, using ImageLab® (Bio-Rad). Finally, for electrophoretic 193 
bands in which more than one protein was identified by MALDI-TOF-TOF, their 194 
percentage distributions were estimated on the basis of the corresponding intensities of 195 
the intact protein ions, as observed in the nESI-MS analysis. Intensities lower than 5% 196 
(relative to the major protein ions in such mixtures) were considered as traces. 197 
 198 
2.5 Adenosine analysis 199 
 The presence of the nucleoside adenosine was determined by spiking a sample of 200 
2 mg of venom with 10 μg of adenosine and separating it by RP-HPLC as described in 201 
section 2.2. If the adenosine coincided with a peak already present in a crude venom 202 
sample (as judged by the increment in the height of the peak), and if this venom peak 203 
showed an ESI-MS spectrum essentially identical to adenosine, the identity of venom 204 
component was judged to be adenosine. Further confirmation of the molecular identity 205 
of adenosine was obtained by acquiring its collision-induced dissociation MS/MS 206 
spectrum in positive mode, using the Enhanced Product Ion tool of Analyst v1.5 in the 207 
QTrap3200 mass spectrometer, to show the expected reporter ion transition 268 → 136. 208 
Nucleoside abundance was estimated by deriving un-spiked nucleoside concentration 209 
from integrating the areas of both spiked and un-spiked chromatographic peaks. 210 
 211 
2.6 In vitro enzymatic activities 212 
2.6.1. Phospholipase A2 activity 213 
Assay of PLA2 activity was carried out using the monodisperse synthetic 214 
chromogenic substrate 4-nitro-3-octanoyloxybenzoic acid (NOBA) [25]. Twenty-five 215 
μL of solution containing various amounts of venom were mixed with 200 μL of 10 mM 216 
Tris, 10 mM CaCl2, 0.1 M NaCl, pH 8.0, and 25 μL of NOBA to achieve a final 217 
substrate concentration of 0.32 mM. Plates were incubated at 37 °C for 60 min, and 218 
absorbances were recorded at 405 nm in a microplate reader. For comparative purposes, 219 
the activities of the venoms of D. polylepis and the viperid snake Bothrops asper were 220 
also assessed. 221 
 222 
2.6.2 Proteinase activity 223 
Proteinase activity was assayed by adding 20 µg of venom to 100 μL of 224 
azocasein (10 mg/mL in 50 mM Tris–HCl, 0.15 M NaCl, 5 mM CaCl2 buffer, pH 8.0), 225 
and incubated for 90 min at 37 °C. The reaction was terminated by addition of 200 μL 226 
of 5% trichloroacetic acid, and after centrifugation (5 min, 6000 g), 150 μL of 227 
supernatants were mixed with 100 μL of 0.5 M NaOH, and absorbances were recorded 228 
at 450 nm. The absorbance of azocasein incubated with distilled water alone was used 229 
as a blank, being subtracted from all readings [26]. For comparative purposes, the 230 
activities of the venoms of D. polylepis and the viperid snake Bothrops asper were also 231 
assessed. 232 
 233 
2.7 Toxicological profiling 234 
2.7.1 Animals  235 
 In vivo assays were performed in CD-1 mice of both sexes, provided by Instituto 236 
Clodomiro Picado, following protocols approved by the Institutional Committee for the 237 
Use and Care of Animals (CICUA), University of Costa Rica. Mice were provided food 238 
and water ad libitum. 239 
 240 
2.7.2 Toxicity of crude venom and isolated venom fractions 241 
 The lethality of the whole venom and venom fractions was tested by intravenous 242 
(i.v.) injection in groups of four mice (18–20 g body weight). Various amounts of 243 
venom or venom fractions were dissolved in phosphate-buffered saline (PBS; 0.12 M 244 
NaCl, 0.04 M sodium phosphate buffer, pH 7.2) and injected in the caudal vein, in a 245 
volume of 100 µL. Deaths occurring within 24 h were recorded, and LD50s were 246 
calculated by probits [27], using the BioStat® software (AnalySoft). 247 
The acute toxicity of venom fractions was initially screened by selecting a dose 248 
based on fraction abundance in the venom and assuming a venom yield of 75 mg for D. 249 
angusticeps (http://snakedatabase.org/pages/LD50.php#legendAndDefinitions), 250 
Laustsen et al.’s Toxicity Score [20], and 50 kg as the weight of a human being. On this 251 
basis, a cutoff dose (mg/kg) was selected and tested for each fraction. Fractions that 252 
were not lethal at this dose (corresponding to a Toxicity Score below 7) were considered 253 
as having insignificant acute toxicity, whereas fractions which did kill mice at this level 254 
were further evaluated, and precise LD50s were determined for them. 255 
 256 
2.8 Antivenoms 257 
 Polyspecific antivenoms from the following manufacturers were used: (a) 258 
SAIMR (South African Institute for Medical Research) Polyvalent Snake Antivenom 259 
from South African Vaccine Producers (Pty) Ltd (batch number BC02645, expiry date 260 
07/2016); (b) Snake Venom Antivenom (Central Africa) from VINS Bioproducts Ltd 261 
(batch 12AS13002, expiry date 04/2017); (c) Snake Venom Antivenom (African) from 262 
VINS Bioproducts Ltd (batch 13022, expiry date 01/2018). In addition, the 263 
monospecific Micrurus nigrocinctus Anticoral Antivenom from Instituto Clodomiro 264 
Picado (batch 5310713ACLQ, expiry date 07/2016) was used for comparison in certain 265 
experiments. 266 
 267 
2.9 Immunoreactivity of antivenoms against crude venom and venom fractions by ELISA 268 
 Wells in MaxiSorp plates (NUNC, Roskilde, Denmark) were coated overnight 269 
with 1.0 μg of each HPLC venom fraction, or crude venom, dissolved in 100 μL PBS. 270 
After a washing step, wells were blocked by adding 100 μL PBS containing 2% (w:v) 271 
bovine serum albumin (BSA, Sigma), and incubated at room temperature for 1 h. Plates 272 
were then washed five times with PBS. A dilution of each antivenom in PBS + 2% BSA 273 
was prepared. 100 μL of antivenom solution was added to each well in triplicates and 274 
incubated for 2 h. Plates were then washed five times with PBS. 100 µL of a 1:2000 275 
dilution of conjugated antibody (Sigma A6063, rabbit anti-horse IgG (whole molecule)-276 
alkaline phosphatase in PBS + 1% BSA) was then added to each well. The plates were 277 
incubated for 2 h, and then washed five times with FALC buffer (0.05 M Tris, 0.15 M 278 
NaCl, 20 PM ZnCl2, 1 mM MgCl2, pH 7.4). Development of color was attained by 279 
addition of 100 µL p-nitrophenyl phosphate (1 mg/mL in 9.7% v/v diethanolamine 280 
buffer, pH 9.8) and absorbances at 405 nm were recorded (Multiskan FC, Thermo 281 
Scientific). 282 
 283 
2.10 Double immunodiffusion of antivenoms against venoms from D. polylepis and D. 284 
angusticeps 285 
Agarose was dissolved in 30 mL of PBS to attain 1% concentration, and poured 286 
into a Petri dish. Six holes were punched in the gel, and 50 µl of antivenom was placed 287 
in the center well, while 30 µl of solutions of D. angusticeps and D. polylepis venoms 288 
were added to the surrounding wells at variable concentrations (0.5, 1 and 2 µg/µL). 289 
After overnight incubation at room temperature, agarose gels were photographed using 290 
a ChemiDoc® recorder and ImageLab® software. 291 
 292 
2.10 Neutralization studies with antivenoms 293 
Mixtures containing a fixed amount of venom and variable dilutions of 294 
antivenoms were prepared using PBS as diluent and incubated at 37 ºC for 30 min. 295 
Controls contained PBS instead of antivenom. Aliquots of 100 µL of the solutions, 296 
containing 4 LD50s of venom (64 µg/mouse), were then injected i.v. into groups of four 297 
mice (18-20 g). Deaths occurring within 24 h were recorded for determining the 298 
neutralizing capacity of antivenoms. Neutralization was expressed as the Median 299 
Effective Dose (ED50) of antivenom, defined as the ratio mg venom/mL antivenom at 300 
which 50% of the injected mice were protected. The ED50s as estimated by probits, as 301 
described in Section 2.6.2.  302 
 303 
3.0 Results and Discussion 304 
3.1 Venomics 305 
SDS-PAGE separation of venom proteins revealed similarities and differences 306 
between the venoms of D. angusticeps and D. polylepis (Figure 2). Both venoms 307 
showed predominantly low molecular mass bands, in addition to a number of bands of a 308 
wide range of molecular masses, including some large proteins with molecular masses 309 
above 100 kDa. When SDS-PAGE was run under non-reducing conditions, the venom 310 
of D. angusticeps showed more bands than that of D. polylepis. In particular, D. 311 
angusticeps venom presented three bands of molecular masses between 18 and 22 kDa, 312 
which were absent in the venom of D. polylepis. In turn, D. polylepis venom had a band 313 
of 37 kDa, absent in D. angusticeps venom. In contrast, with the exception of a 25 kDa 314 
band in the venom of D. angusticeps, the majority of these intermediate molecular mass 315 
bands were not observed in reduced gels, indicating that these bands were comprised of 316 
higher order protein complexes. 317 
A bottom-up proteomic characterization of D. angusticeps venom was carried 318 
out. Using RP-HPLC, the venom was resolved into 29 fractions, where the first three 319 
eluting from the column did not contain proteins as evidenced by electrophoresis. After 320 
SDS-PAGE separation, the remaining 26 fractions were resolved into 63 bands (Figure 321 
3), of which 59 resulted in positive identifications upon in-gel digestion and MALDI-322 
TOF-TOF analysis, whereas 4 remained unknown. In total, 42 different proteins were 323 
identified within these bands (Table 1). In certain cases, exemplified by fraction number 324 
5, the bands separated by SDS-PAGE contained the same protein in both monomer and 325 
dimer forms. 326 
 Fractions 1-3 did not contain proteins according to SDS-PAGE. Due to its high 327 
abundance, fraction 1 was analyzed by direct infusion using nESI-MS/MS, which 328 
revealed a component with a molecular mass of 268 Da. Upon collision-induced 329 
dissociation, this ion produced a fragment of 136 Da, corresponding to the characteristic 330 
transition of adenosine. Furthermore, spiking with adenosine as described in section 2.5, 331 
provided an estimation that 0.75% of the chromatographic signal of the venom 332 
corresponded to this nucleoside. Presence of a substantial amount of adenosine was also 333 
observed in the venom of D. polylepis [19]. Adenosine might play an auxiliary role in 334 
the toxicity of mamba venoms owing to its vasodilatory effect, as previously suggested 335 
[19]. 336 
The overall protein composition of D. angusticeps venom was determined by 337 
assigning the identified proteins to families and expressing these as percentages of total 338 
protein content (Figure 4). The most abundant components belong to the three-finger 339 
toxin family (3FTx; 69.2%) and the family of Kunitz-type proteinase inhibitors, which 340 
includes the dendrotoxins (KUN; 16.3%). The 3FTxs in elapid venoms all share a 341 
common structural architecture with a distinct protein fold, comprising between 60 and 342 
80 amino acids in length, containing a small, globular, hydrophobic core with four or 343 
five conserved disulfide bridges, from which three β-stranded loops extend [28–30]. 344 
This makes this group of toxins resemble three outstretched fingers [31]. Despite the 345 
common structural motif, a diverse array of functions has been associated with 3FTxs 346 
[32]. 347 
All 3FTxs found in D. angusticeps venom belong to the short chain subfamily, 348 
but attained to different sub-subfamilies (Figure 4). The majority of 3FTxs in this 349 
venom belong to the Orphan Group XI (from Toxin FV-III), whose function has not yet 350 
been established [29], followed by aminergic toxins (Muscarinic toxin 2, Muscarinic 351 
toxin 4, Synergistic-like protein, and Adrenergic toxins) [16]. A further 8.4% of 3FTxs 352 
were attained to fasciculins (all from the acetylcholinesterase inhibitory sub-subfamily), 353 
which are unique to D. angusticeps [33].  354 
Interestingly, the proteomic analysis of the 3FTxs of D. angusticeps venom did 355 
not reveal the presence of D-neurotoxins, perhaps the most studied 3FTxs from elapid 356 
venoms. D-neurotoxins bind with high affinity to the nicotinic cholinergic receptor at 357 
the motor end-plate of the neuromuscular junction, causing a blockage in neuromuscular 358 
transmission and flaccid paralysis, generally inducing death by respiratory failure [34]. 359 
D-neurotoxins show the highest Toxicity Score values among the fractions of D. 360 
polylepis venom  [19]. Their absence in the venom of D. angusticeps marks a significant 361 
difference between these two mamba venoms and suggests that the predominant 362 
mechanisms for prey immobilization in these venoms might be different. 363 
Another type of neurotoxins unique to the Dendroaspis genus, and found in our 364 
proteomic analysis of D. angusticeps venom, is comprised by the dendrotoxins, which 365 
are homologous to Kunitz-type serine proteinase inhibitors [35]. Dendrotoxins interact 366 
and inhibit the presynaptic voltage-gated potassium channels, thus exerting a facilitatory 367 
effect associated with excitability [18,35]. The venom of D. angusticeps has a lower 368 
relative content of Kunitz-type proteinase inhibitors, but a higher content of 3FTxs, 369 
when compared to the venom of D. polylepis [19]. The combined action of the 370 
fasciculins and dendrotoxins results in enhanced skeletal muscle excitability and 371 
contraction, probably leading to respiratory arrest.  372 
Other protein families found in lower proportions in the venom of D. 373 
angusticeps include metalloproteinases (SVMP; 6.7%), cysteine-rich secretory proteins 374 
(CRISP; 2.1%), and traces of Galactose-binding lectins (GAL; < 0.5%), peptidases 375 
(PEP; < 0.1%), hyaluronidases (HYA; < 0.3%), and nerve growth factors (NGF < 0.1%) 376 
(Figure 4).  An extremely low PLA2 activity was observed in vitro for D. 377 
angusticeps venom (Figure 5A), in agreement with previous findings [36]. The 378 
proteomic analysis, however, did not identify any PLA2 in this venom, implying that 379 
such enzyme would be present only in trace amounts. Alternatively, the very low PLA2 380 
activity recorded for this venom may correspond to low levels of non-specific 381 
hydrolysis of the NOBA synthetic substrate caused by other enzymes. The negligible 382 
content of PLA2s in Dendroaspis venoms contrasts with the characteristic high amounts 383 
and activity of this enzyme in many other elapid venoms [37,38]. Also, despite the 384 
presence of 6.7% of SVMPs in the venom proteome, very low proteinase activity was 385 
observed for D. angusticeps venom when using azocasein as substrate (Figure 5B). This 386 
observation mirrors the negligible activity described for D. polylepis venom [19]. It is 387 
likely that Dendroaspis SVMPs have a restricted substrate specificity, as occurs in 388 
SVMPs from other elapid venoms [39,40]. 389 
 390 
3.2. Toxicity of venom fractions 391 
 Toxicity testing was performed for most venom fractions (Table 2). Using the 392 
Toxicity Score defined by Laustsen et al. [20], a cut-off Toxicity Score value of 7, 393 
below which a fraction would be deemed to not be of medical relevance for lethality, 394 
was chosen for screening the fractions. From Table 2 it is evident that the vast majority 395 
of the fractions did not induce lethality in mice when tested individually. Only fraction 396 
8 (containing Rho-elapitoxin-Da1b and Fasciculin-2) was shown to be lethal at the 397 
doses tested, with an LD50 of 0.58 mg/kg (95% confidence limits: 0.17-1.23 mg/kg) and 398 
a toxicity score of 10.9. A previous study showed that an ‘angusticeps-type’ toxin, 399 
which corresponds to a fasciculin, induced respiratory arrest in mice within minutes 400 
after an i.v. injection of a dose of 1 mg/kg, and also caused cardiovascular alterations 401 
[41]. Nevertheless the Toxicity Score of fraction 8 contrasts with the overall Toxicity 402 
Score of 117.6 for the whole venom, suggesting that different toxins in D. angusticeps 403 
venom may act in a synergistic manner, thereby potentiating each other’s toxic effects, 404 
leading to higher toxicity for whole venom. To further investigate the possible 405 
synergism between toxins in the venom, fractions 4-12 were combined in equivalent 406 
amounts (according to mass), and the LD50 was determined to be 1.36 mg/kg (95% 407 
confidence limits: 0.96-1.66 mg/kg), corresponding to a Toxicity Score of 51.7, 408 
providing further evidence for the presence of synergism. The identity of the toxins 409 
acting synergistically is presently unknown; however, it is suggested that fasciculins and 410 
dendrotoxins, and probably other synergistically acting proteins, might be involved in 411 
this phenomenon. It should be kept in mind that the solvents used in RP-HPLC 412 
separation, particularly acetonitrile, denature some venom components, especially 413 
SVMPs; thus, the toxicity of SVMP fractions cannot be assessed with our approach. 414 
Nevertheless, elapid SVMPs are unlikely to play a key role in lethality. In support of 415 
this, it was previously shown that the LD50 of D. polylepis venom was not significantly 416 
altered after incubating venom with RP-HPLC solvents [19].   417 
 Despite its lack of D-neurotoxins, the venom of D. angusticeps is quite effective 418 
in killing mice rapidly after injection, as observed in our toxicity experiments with 419 
crude venom, where the controls receiving 4 LD50s of venom on average died within 10 420 
minutes. Previous studies highlighted two main toxic activities when D. angusticeps 421 
whole venom is tested in experimental systems. On various nerve-muscle preparations, 422 
this venom augmented the responses to indirect stimulation [35], possibly due to the 423 
combined action of dendrotoxins and fasciculins. Then, prolonged exposure to higher 424 
venom concentrations resulted in failure of muscle contraction. Additionally, the venom 425 
induced hypotension in various animal models, an effect that was blocked by the 426 
muscarinic cholinergic antagonist atropine [42]. This effect could be caused by the 427 
3FTxs, previously characterized from this venom, that act on muscarinic cholinergic 428 
and adrenergic receptors [14–16]. Thus, the combined action of the various neurotoxin 429 
types present in D. angusticeps venom may result in a complex series of neuromuscular 430 
and cardiovascular effects, which result in effective prey immobilization in the absence 431 
of the action of D-neurotoxins. This toxicological scenario, and the existence of 432 
synergistic effects, complicates the selection of the most relevant toxins towards which 433 
antibodies should be raised in order to abrogate venom toxicity. This challenging task 434 
demands the identification of the most relevant synergistic toxins.   435 
 436 
3.3 Immunoprofiling and neutralizing ability of antivenoms  437 
Three polyspecific antivenoms, which are distributed in sub-Saharan Africa, 438 
were investigated for their ability to neutralize D. angusticeps venom and their ability to 439 
recognize both whole venoms and venom fractions. The SAVP antivenom showed the 440 
highest neutralizing ability against D. angusticeps venom, with an ED50 (mg venom 441 
neutralized per mL antivenom) of 4.0 mg/mL (95% confidence limits: 1.7-10.0 mg/mL). 442 
VINS African antivenom also neutralized the lethal activity of the venom, with an ED50 443 
of 2.4 mg/mL (95% confidence limits: 1.4-4.0 mg/mL). On the other hand, VINS 444 
Central African antivenom failed to neutralize D. angusticeps venom at the lowest 445 
venom/antivenom ratio tested (1.0 mg venom/mL antivenom). These results bear a 446 
relationship with the fact that the venom of D. angusticeps is included in the 447 
immunization mixture for the manufacture of SAVP antivenom, whereas the two VINS 448 
antivenoms do not include this venom during immunization. The two VINS products 449 
do, however, include the venoms of other Dendroaspis species, according to their leaflet 450 
information. Gel immunodiffusion tests of the three antivenoms indeed revealed that 451 
cross-reactive antigens between D. angusticeps and D. polylepis venoms exist, 452 
evidenced by the SAVP antivenom, which produced the strongest precipitin bands with 453 
identity or partial identity patterns (Figure 6). Cross-reactivity between at least some 454 
components of these two venoms would explain the neutralization obtained with the 455 
VINS antivenom, despite these being produced without using D. angusticeps venom. It 456 
would be relevant to perform detailed studies on the antigenic relationships of the main 457 
toxicologically-relevant components of Dendroaspis venoms, such as the various types 458 
of 3FTxs and dendrotoxins, in order to have a knowledge base for selecting the venoms 459 
or toxins to be used for preparing antivenoms. Interestingly, gel immunodiffusion 460 
results, regarding the intensity of precipitates, showed a better correlation with the 461 
neutralization potencies observed for the three antivenoms compared to their ELISA 462 
titration curves against immobilized crude venoms, which showed only minor 463 
differences in binding among them (Figure 7). Although the SAVP antivenom displays 464 
a slightly stronger binding when comparing the three antivenoms on the basis of 465 
volume, differences are less evident when the antivenoms are evaluated based on their 466 
protein concentrations (Figure 7). In general, solid-phase immunoassays of antivenoms 467 
against crude venoms do not always predict their neutralizing efficacy, as antibodies 468 
may bind to highly immunogenic venom components that may not have a key role in 469 
toxicity. 470 
To further investigate the immunorecognition patterns of the antivenoms, 471 
binding of their antibodies to the different venom fractions was measured by ELISA. 472 
From Figure 8, it is evident that a somewhat similar recognition pattern exists for the 473 
different antivenoms. However, not only does the SAVP antivenom in general display 474 
stronger binding to the venom fractions compared to the VINS antivenoms, but SAVP 475 
antivenom also shows a much stronger binding to the fractions in the first part of the 476 
chromatogram (4-10), containing the 3FTxs and the dendrotoxins. These findings, based 477 
on the use of immobilized venom fractions rather than crude venoms, better agree with 478 
the in vivo neutralization studies described above. 479 
Observations performed on mice injected with mixtures of venom and 480 
antivenom in the neutralization experiments revealed that, at some venom/antivenom 481 
ratios, mice were protected from death, but nevertheless showed evident manifestations 482 
of toxicity, such as reduced mobility (without paralysis) and congestion of the eyes. 483 
This suggests that toxins responsible for these effects are not fully neutralized, at some 484 
of the tested venom/antivenom ratios. Since these toxins may play an important role in 485 
envenomings, it would be relevant to assess whether these non-lethal manifestations of 486 
toxicity are neutralized or not in the evaluation of an antivenom. For instance, in the 487 
case of SAVP antivenom, complete neutralization of lethality and of these additional 488 
manifestations was observed at a venom/antivenom ratio of 1.0 mg/mL. In contrast, at 489 
ratios of 2 and 3 mg venom/mL antivenom, lethality was abrogated, but reduced 490 
mobility and eye congestion were present to some extent. At ratios of 4 mg venom/mL 491 
antivenom and higher, lethality was not completely neutralized. Similar observations 492 
were performed with VINS African antivenom, whereby complete neutralization of 493 
lethality and the other effects was achieved at 0.5 mg venom/mL antivenom, whereas at 494 
1 mg/mL the additional effects were observed, and lethality was abrogated. These 495 
findings underscore the relevance of identifying the most relevant toxins in the venom 496 
of D. angusticeps in order to ensure that neutralizing antibodies against them are 497 
included in heterologous or recombinant antivenoms in the future. 498 
  499 
4.0 Concluding remarks and outlook 500 
The venom proteome of D. angusticeps was characterized by a bottom-up 501 
approach. It shows a predominance of 3FTxs and Kunitz-type proteinase inhibitors, 502 
with additional less abundant components of various protein families. A remarkable 503 
feature of this venom is the absence of D-neurotoxins, in sharp contrast with the venom 504 
of the closely related species D. polylepis. The toxicity analysis of RP-HPLC fractions 505 
revealed that only one fraction was lethal to mice at the doses tested, and that the 506 
lethality of whole venom was much higher than what would be expected based on the 507 
lethality of individual fractions. This highlights the presence of synergism between 508 
various venom components, such as dendrotoxins, fasciculins, and probably aminergic 509 
3FTxs of various types. South African polyvalent antivenom and one Indian antivenom 510 
were effective in the neutralization of venom lethality, in agreement with a pattern of 511 
immunorecognition of the various RP-HPLC fractions. On the basis of the synergism 512 
observed in the overall toxicity of this venom, the development of an effective 513 
combination of recombinant neutralizing antibodies demands the identification of the 514 
most relevant synergistic toxins that need to be neutralized – a task that awaits future 515 
research efforts.  516 
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Figure legends 649 
 650 
Figure 1: (A) Dendroaspis angusticeps (B) Distribution of D. angusticeps in Africa.  651 
 652 
Figure 2: SDS-PAGE comparing crude venom of Dendroaspis angusticeps and D. 653 
polylepis under non-reduced (A) and reduced (B) conditions. Various amounts of each 654 
venom were separated in 15% gels and stained with Coomassie Blue G-250. Molecular 655 
mass markers (M) are labeled to the right, in kDa. 656 
 
Figure 3: Separation of Dendroaspis angusticeps venom proteins using RP-HPLC (A), 657 
followed by SDS-PAGE (B). Two mg of venom were fractionated on a C18 column and 658 
eluted with an acetonitrile gradient (dashed line), as described in Methods. Further 659 
separation of protein fractions was performed by SDS-PAGE under reducing 660 
conditions. Molecular weight markers (M) are indicated in kDa. Coomassie-stained 661 
bands were excised, in-gel digested with trypsin, and subjected to MALDI-TOF/TOF 662 
analysis for assignment to protein families, as shown in Table 1.  663 
 664 
Figure 4: Composition of the Dendroaspis angusticeps venom proteome according to 665 
protein families (A) and three-finger toxin sub-subfamilies (B), expressed as 666 
percentages of total protein content. KUN: Bovine pancreatic trypsin inhibitors/Kunitz 667 
inhibitors (dendrotoxins); 3FTx: Three-finger toxins; SVMP: Metalloproteinases; 668 
GAL: Galactose-binding lectins; PEP: Peptidases; HYA: Hyaluronidases; KTC: 669 
Prokineticins; NGF: Nerve growth factors. CRISP: Cysteine-rich secretory proteins. 670 
*Proteins in this fraction (Mambalgins) are not classified to a sub-subfamily; however 671 
they are known to inhibit acid sensing ion channels. MIX: Fractions of different 672 
members of the 3FTx family for which percentages were not determined; sub-673 
subfamilies in this group include: Aminergic toxin, Antiplatelet toxin, Orphan group XI, 674 
and Acid sensing ion channel inhibitor. 675 
 676 
Figure 5: (A) Comparison of the phospholipase A2 activity of 20 µg of the venoms of 677 
Dendroaspis angusticeps, Dendroaspis polylepis, and Bothrops asper, on 4-nitro-3-678 
octanoyloxybenzoic acid synthetic substrate. (B) Comparison of the proteolytic activity 679 
of 40 µg of venoms of D. angusticeps, D. polylepis, and B. asper, on azocasein 680 
substrate. Venoms from both species of Dendroaspis show extremely low 681 
phospholipase A2 and proteinase activities. Each bar represents mean ± SD of 682 
triplicates. 683 
 684 
Figure 6: Gel immunodiffusion assay of antivenoms against the venoms of 685 
Dendroaspis angusticeps (Da) and Dendroaspis polylepis (Dp). Antivenoms (50 PL) 686 
were added to the central wells, and solutions of various concentrations of venoms (30 687 
PL) were added to peripheral wells. (A): VINS African antivenom. (B): VINS Central 688 
Africa Antivenom. (C): SAVP antivenom. (D): Micrurus nigrocinctus antivenom. 689 
 690 
Figure 7: ELISA titrations of antivenoms against immobilized crude venoms of 691 
Dendroaspis angusticeps (A and C) and Dendroaspis polylepis (B and D) SAVP: 692 
SAIMR Polyvalent Snake Antivenom from South African Vaccine Producers, VINS 693 
African: Snake Venom Antiserum (African) from VINS Bioproducts Ltd., VINS 694 
Central Africa Snake Venom Antiserum (Central Africa) from VINS Bioproducts Ltd. 695 
Normal horse serum was used as a negative control. Each point represents mean r SD 696 
of triplicate wells. Antivenom titrations are represented as volumetric dilutions in A and 697 
B, or as protein concentrations in C and D. 698 
 699 
Figure 8: ELISA-based immunoprofiling of antivenoms against HPLC fractions of 700 
Dendroaspis angusticeps venom. Binding of the equine antibodies to the immobilized 701 
venom fractions was detected as described in Methods. Normal horse serum was used as 702 
a negative control. For identification of venom fractions see Table 2. (A) SAVP: 703 
SAIMR Polyvalent Snake Antivenom from South African Vaccine Producers. (B): 704 
VINS African: Snake Venom Antiserum (African) from VINS Bioproducts Ltd., VINS 705 
Central Africa Snake Venom Antiserum (Central Africa) from VINS Bioproducts Ltd. 706 
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as defined as the ratio of protein fraction abundance (%
) in the venom
 divided by its estim
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ix indicates that the fraction did not contain a pure, isolated toxin, but instead a m
ixture of 2–4 different toxins in variable ratios indicated in 
the table.  
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